We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Trinity Biotech

Trinity Biotech develops, manufactures and markets diagnostic test kits for the clinical laboratory and point-of-care... read more Featured Products: More products

Download Mobile App




Rapid Syphilis Test Evaluated as Tool for Public Health Programs

By LabMedica International staff writers
Posted on 09 Nov 2016
A rapid commercial treponemal syphilis-screening test is a new tool for public health programs to combat increasing syphilis rates, specifically among persons without a prior syphilis infection.

The Syphilis Health Check (SHC) test can be performed by non-laboratorian healthcare personnel and results are available in 10 minutes and have recently received a Clinical Laboratory Improvement Amendments waiver.

Scientists at the Florida Department of Health (Tampa, FL, USA) in collaboration with The Centers of Disease Control and Prevention (CDC, Atlanta, GA, USA) evaluated the performance of SHC in comparison with treponemal and nontreponemal tests routinely used in its sexually transmitted disease (STD) clinic. More...
For this evaluation, patients seeking sexually transmitted diseases (STD) testing at the Florida Department of Health STD clinic in Escambia County during March 11 to April 21, 2016, were tested for syphilis using the SHC on blood specimens obtained by fingerstick; a venous blood specimen was drawn concurrently and submitted for treponemal and testing at the state public health laboratory.

Trep-Sure qualitative enzyme immunoassay (EIA) reference treponemal test was used as the standard for “true” positive or negative treponemal test results, when evaluating the SHC. The rapid plasma reagin (RPR) card for syphilis was also tested. The SHC was used to screen 202 patients for syphilis. Among these patients, 171 (85%) were nonreactive on all syphilis tests (SHC, EIA, and RPR), 26 (13%) had a reactive SHC, and five (2%) had a nonreactive SHC, but had one or more reactive tests at the state laboratory.

Among the 26 reactive SHCs, 10 (38%) had a reactive EIA (six had a reactive RPR), and 16 (62%) were not confirmed by EIA or RPR at the state laboratory. For the six reactive SHC patients with reactive EIA and reactive RPR, three were staged as secondary syphilis, one as primary syphilis, one as early latent syphilis, and one was a previously treated positive with no increase in titer since last testing. Among the five specimens that were reactive on other tests but SHC nonreactive, only one was both RPR (1:8 serum dilution) and EIA reactive. The sensitivity of SHC was 71.4% when compared with the Trep-Sure (EIA) reference treponemal test. The specificity of the SHC compared with the reference treponemal test was 91.5%. The study was published on October 28, 2016, in the journal Morbidity and Mortality Weekly Report.

Related Links:
Florida Department of Health
The Centers of Disease Control and Prevention

New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.